Retinal disease management has witnessed remarkable advances in posterior segment
pharmacotherapy with the development of anti-VEGF molecules such as Lucentis® …

Purpose To review the biosimilars of anti–vascular endothelial growth factor agents for
retinal diseases and provide an update about their development. Design Literature review …

Age-related macular degeneration (AMD) is a leading cause of visual impairment and
blindness in older adults. The prognosis for the neovascular type of advanced AMD …

Introduction Age-related macular degeneration (AMD) is a major cause of central visual loss
in the developed world. Although the pathogenesis is not fully understood, vascular …

Diabetic macular edema (DME) is a major ocular complication of diabetes mellitus (DM),
leading to significant visual impairment. DME's pathogenesis is multifactorial. Focal edema …

Neovascularization of the macula, a common complication of many chorioretinal diseases
such as neovascular age-related macular degeneration, polypoidal choroidal vasculopathy …

Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-
retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor …

Purpose This article aims to analyse the key regulatory guidelines across the globe
concerning biosimilars. Materials and methods Review of the current literature. Results …

Objective To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5
mg in treatment-naïve patients with branch retinal vein occlusion (BRVO) enrolled in the …

Abstract Introduction The REal life assessmENt of safety And effeCTiveness of Razumab
(RE-ENACT) and long-term RE-ENACT 2 retrospective studies have evaluated the use of …